Since REGENXBIO Inc. (NASDAQ:RGNX) and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AMAG Pharmaceuticals Inc.||474.00M||1.22||169.34M||-4.73||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 shows us the net margins, return on assets and return on equity of both companies.
|Net Margins||Return on Equity||Return on Assets|
|AMAG Pharmaceuticals Inc.||-35.73%||-5.3%||-2.4%|
The Current Ratio of REGENXBIO Inc. is 20.2 while its Quick Ratio stands at 20.2. The Current Ratio of rival AMAG Pharmaceuticals Inc. is 2.9 and its Quick Ratio is has 2.7. REGENXBIO Inc. is better equipped to clear short and long-term obligations than AMAG Pharmaceuticals Inc.
In next table is delivered REGENXBIO Inc. and AMAG Pharmaceuticals Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|AMAG Pharmaceuticals Inc.||1||0||0||1.00|
On the other hand, AMAG Pharmaceuticals Inc.’s potential upside is 7.72% and its average price target is $18.
Institutional & Insider Ownership
Roughly 81.5% of REGENXBIO Inc. shares are owned by institutional investors while 0% of AMAG Pharmaceuticals Inc. are owned by institutional investors. 1.2% are REGENXBIO Inc.’s share owned by insiders. Comparatively, 1.8% are AMAG Pharmaceuticals Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|AMAG Pharmaceuticals Inc.||-1.22%||-4.45%||-26.78%||-26.02%||26.45%||34.57%|
For the past year REGENXBIO Inc.’s stock price has bigger growth than AMAG Pharmaceuticals Inc.
REGENXBIO Inc. beats on 10 of the 12 factors AMAG Pharmaceuticals Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV vectors to various other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.